Abstract 437P
Background
Sarcopenia, characterized by a decline of skeletal muscle plus low muscle strength and/or physical performance, has emerged to be an important prognostic factor for advanced cancer patients. Sarcopenia is diagnosed if there is decreased muscle mass and either decreased muscle function or physical activity. The diagnostic tools for evaluating muscle mass in cancer patients was using muscle index derived from abdominal CT scan. However, the practicability of using CT scan for screening decreased muscle mass has been questioned. Until know there is limited data diagnostic value of Bio-impedance analysis (BIA) in cancer patients. The aim of this study is to know the correlation between BIA and abdominal CT scan to diagnose decreased muscle mass in cancer patients.
Methods
This cross-sectional study included adult cancer patients who underwent abdominal CT scans in purpose for diagnostic. BIA was performed in the same day when CT-scan was performed. CT-scans was analyzed using special software. BIA was performed using standing-posture 2-electrode BIA device BC-418 (BIA, Tanita Corp, Tokyo, Japan). Height adjusted appendicular skeletal muscle mass (ASM) was calculated from BIA. Height adjusted skeletal muscle Index (SMI) was performed from a single cross-sectional CT image (slice) at third lumbar (L3) for abdominal skeletal muscle area. We calculated Pearson’s r correlation coefficient between two parameters.
Results
A total of 39 patients were included. Twenty-eight (71.8%) patients were female. The mean of age was 51.18 +13.83 years old. Several type of cancer such as breast, lung, gastrointestinal and genitourinary cancer were included. Eleven (28.2%) patients were in advanced stage. Mean of height adjusted BIA was 6.60 + 0.98 kg/m2. Mean of height adjusted muscle mass was 42.25 + 7.57 cm2/m2. BIA and CT-derived muscle were moderately correlated (r = 0.72, p < 0.001).
Conclusions
This study showed that BIA- and CT-derived muscle mass was moderately correlated in adult cancer patients. Further research is needed to confirm this result.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract